Evidence map›Paper›PMID 14767479›Full record

ArticleNature cell biology2004

Non-proteolytic inactivation of geminin requires CDK-dependent ubiquitination.

Anatoliy Li, J Julian Blow

Open access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. ThemBio · 2017
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Quaternary structure of the human Cdt1-Geminin complex regulates DNA replication licensing.Proceedings of the National Academy of Sciences of the United States of America · 2009
    Article
  16. Article
  17. Article
  18. Geminin stabilizes Cdt1 during meiosis in Xenopus oocytes.The Journal of biological chemistry · 2009
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Anatoliy LiWellcome Trust Biocentre, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
J Julian Blow
University of Dundee · GBWellcome Trust · GB

Funding

Cancer Research UK A3135
6 · The paper itself

Abstract

In late mitosis and G1, a complex of the essential initiation proteins Mcm2-7 are assembled onto replication origins to 'license' them for initiation. At other times licensing is inhibited by cyclin-dependent kinases (CDKs) and geminin, thus ensuring that origins fire only once per cell cycle. Here we show that, paradoxically, CDKs are also required to inactivate geminin and activate the licensing system. On exit from metaphase in Xenopus laevis egg extracts, CDK-dependent activation of the anaphase-promoting complex (APC/C) results in the transient polyubiquitination of geminin. This ubiquitination triggers geminin inactivation without requiring ubiquitin-dependent proteolysis, and is essential for replication origins to become licensed. This reveals an unexpected role for CDKs and ubiquitination in activating chromosomal DNA replication.

Indexed as

Anaphase-Promoting Complex-CyclosomeAnimalsCell Cycle ProteinsCell ExtractsCell-Free SystemChromosomesCyclin-Dependent KinasesDNA ReplicationFemaleG1 PhaseGemininMaleMetaphaseMitosisOvumPeptide HydrolasesAnaphase-Promoting Complex-CyclosomeCell Cycle ProteinsCell ExtractsCyclin-Dependent KinasesGemininGMNN protein, XenopusPeptide HydrolasesUbiquitinUbiquitin-Protein Ligase ComplexesXenopus Proteins

Identifiers

PMID14767479
PMCPMC2691133
OpenAlexW2051716255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.